The invention in this patent application relates to 4-aminopyridazin-6-one derivatives represented generally by formula 1. These compounds are inhibitors of the NOD-like receptor protein 3 (NLRP3) inflammasome pathway and may potentially provide a useful treatment for one or more of the diseases and disorders mediated by NLRP3, including but not limited to immune diseases, inflammatory diseases, autoimmune diseases, autoinflammatory fever syndromes, cryopyrin-associated periodic syndrome, chronic liver disease, kidney-related disease, hyperoxaluria, lupus nephritis, Type I and Type II diabetes, nephropathy, neurodegenerative diseases, Alzheimer's disease, cardiovascular diseases, metabolic diseases and many more.

01 Oct 2023·3 Biotech

In silico guided screening of active components of C. lanceolata as 3-chymotrypsin-like protease inhibitors of novel coronavirus

Article

Author: Sharma, Chandra Shekhar ; Mishra, Shashank Shekher ; Sharma, Ganesh ; Kumar, Neeraj

Supplementary Information:

The online version contains supplementary material available at 10.1007/s13205-023-03745-2.

01 May 2023·EBioMedicine

Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance

Article

Author: Ip, Jonathan Daniel ; Umer Abdullah, Syed Muhammad ; Cheuk-Ying Leung, Rhoda ; Kai-Wang To, Kelvin ; Wing-Ho Chu, Allen ; Sun, Yanni ; Chan, Wan-Mui

BACKGROUND:

Nirmatrelvir-ritonavir (Paxlovid) and ensitrelvir are 3-chymotrypsin-like cysteine protease (3CL^pro) inhibitors which have been approved for the treatment of COVID-19 in 2021 and 2022, respectively. Previous studies have identified 3CL^pro mutations that are associated with reduced susceptibility to these antivirals. The aim of the current study was to estimate the global prevalence of 3CL^pro inhibitor-resistant SARS-CoV-2 strains.

METHODS:

We compiled a list of 3CL^pro mutations which have been associated with nirmatrelvir or ensitrelvir resistance based on either viral replication or 3CL^pro activity assays, and determined their prevalence among 13.4 million sequences deposited in GISAID as of December 14, 2022, about 1 year after the approval of nirmatrelvir-ritonavir. We analyzed the prevalence for different time periods, SARS-CoV-2 lineages and geographical locations.

FINDINGS:

Overall, 0.5% (67,095/13,446,588) of the sequences contained at least one mutation that was shown to affect the inhibitory activity of nirmatrelvir or ensitrelvir on viral replication or 3CL^pro activity. We did not observe any increasing trend of resistance after the widespread clinical use of nirmatrelvir-ritonavir. G15S (2070 per million) and T21I (1386 per million) were the most prevalent mutations, and these mutations were dominant in some SARS-CoV-2 lineages. E166V and S144E, previously shown to affect the inhibitory activity of nirmatrelvir on viral replication or protease activity by > 100-folds, were found in <1 per million sequences.

INTERPRETATION:

Our data suggest that 3CL^pro inhibitor resistance is currently rare. However, continuous global genotypic and phenotypic surveillance would be crucial in the early detection of resistant mutants.

FUNDING:

Richard and Carol Yu, May Tam Mak Mei Yin, The Shaw Foundation Hong Kong, Michael Tong, Marina Lee, Government Consultancy Service, the Emergency Key Program of Guangzhou Laboratory (See acknowledgements for full list).

100 Deals associated with ISM036-076

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Preclinical	-	InSilico Medicine, Inc.	24 May 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

ISM036-076

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation